LLG783 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Peripheral Artery Disease (PAD); Intermittent Claudication
Conditions
Peripheral Artery Disease (PAD); Intermittent Claudication
Trial Timeline
Sep 20, 2017 → Dec 27, 2018
NCT ID
NCT03194776About LLG783 + Placebo
LLG783 + Placebo is a phase 2 stage product being developed by Novartis for Peripheral Artery Disease (PAD); Intermittent Claudication. The current trial status is completed. This product is registered under clinical trial identifier NCT03194776. Target conditions include Peripheral Artery Disease (PAD); Intermittent Claudication.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03194776 | Phase 2 | Completed |
Competing Products
20 competing products in Peripheral Artery Disease (PAD); Intermittent Claudication